inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: subjects consented voluntarily to participate the study, subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: subjects consented voluntarily to participate the study, subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol, 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study.

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study, 8. individuals who work in close proximity to others, are in a public facing role, and/or use public transport on a regular basis (≥4 journeys per week).

inclusion criteria: each subject must meet all the following criteria to be enrolled in this study: 1. subjects consented voluntarily to participate the study, 2. subjects agreed to comply with all study visits and procedures (consented to give blood sample and nasopharyngeal swab, and receiving automated telephone calls from the study site), 3. subjects agreed to adhere to the prohibitions and restrictions specified in this protocol, 4. subjects, who are sexually active and have childbearing potential, agreed to comply with the contraceptive requirements to be applied in the study, 5. adult males or females of at least 18 years of age and not older than 55 years of age on the date of the informed consent signature, 6. subjects who are medically stable (those without severe pain, severe swelling, severe movement limitation, persistent high fever, severe headache or other systemic or local reactions) such that who are not anticipated to hospitalize within the study period, according to the judgment of the investigator, and the subjects appears likely to be able to continue the study until the follow-up period specified in the protocol 7. subjects who are excluded from the criteria to receive the covid-19 vaccine approved in the scope of emergency use approval in turkey or subjects who meet the vaccination criteria, but voluntarily chose not to be vaccinated and agreed to receive one of the vaccines to be used in this study, 8. individuals who work in close proximity to others, are in a public facing role, and/or use public transport on a regular basis (≥4 journeys per week).